Opus Genetics
IRD
40 hedge funds and large institutions have $8.07M invested in Opus Genetics in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 3 closing their positions.
468% more call options, than puts
Call options by funds: $1.07M | Put options by funds: $188K
333% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
33% more funds holding
Funds holding: 30 → 40 (+10)
2.61% more ownership
Funds ownership: 9.94% → 12.54% (+2.6%)
6% less capital invested
Capital invested by funds: $8.62M → $8.07M (-$547K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$1.1M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$531K |
| 3 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$359K |
| 4 |
Two Sigma Investments
New York
|
+$333K |
| 5 |
State Street
Boston,
Massachusetts
|
+$245K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.11M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$231K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$124K |
| 4 |
RCM
Regency Capital Management
Honolulu,
Hawaii
|
-$60.1K |
| 5 |
MA
MCF Advisors
Covington,
Kentucky
|
-$49K |
IRD Hedge Fund Activity: Q4 2021 in Review
40 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q4 2021, worth a combined $8.07M — down 6.3% from $8.62M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new IRD positions and 3 closed out — a net gain of 10 holders — while 12 added to existing stakes and 6 trimmed.
The largest buyer was Two Sigma Advisers, adding an estimated $1.1M. The largest seller was Vanguard Group, cutting an estimated $1.11M.
- 40 institutional investors held Opus Genetics (IRD) as of Q4 2021, up from 30 in Q3 2021.
- Funds reported $8.07M of Opus Genetics stock for Q4 2021, down 6.3% quarter-over-quarter.
- 13 funds opened new Opus Genetics positions in Q4 2021 and 3 closed out, a net change of +10 holders.
- The largest Opus Genetics buyer in Q4 2021 was Two Sigma Advisers, an estimated $1.1M added.
- The largest Opus Genetics seller in Q4 2021 was Vanguard Group, an estimated $1.11M sold.
Based on aggregated 13F filings for Q4 2021.